“…Cyclopamine was discovered to inhibit the Hedgehog signaling pathway by direct binding to the G proteinâcoupled receptor Smoothened (Chen et al ., ). As such, cyclopamine has shown promising antineoplastic activities against several cancers in which Hedgehog signaling malfunction is implicated, including pancreatic cancer, renal cell carcinoma, medulloblastoma, basal cell carcinoma, and leukemia (Gailani et al ., ; Taipale et al ., ; Berman et al ., ; Olive et al ., ; Lin et al ., ; Bahra et al ., ; Behnsawy et al ., ). A semiâsynthetic analog of cyclopamine, IPIâ926, has been in clinical trials for treatment of several cancers including pancreatic cancer and leukemia (Olive et al ., ; Tremblay et al ., ; Lin et al ., ).…”